These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 2453860)

  • 21. Intracellular localisation of 5alpha-dihydrotestosterone in human benign prostatic hypertrophy.
    Ghanadian R; Chisholm GD; Fotherby K
    Clin Chim Acta; 1976 Dec; 73(3):521-6. PubMed ID: 63340
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Testicular steroids, prolactin, relaxin and prostate gland markers in peripheral blood and seminal plasma of normal dogs and dogs with prostatic hyperplasia.
    Wolf K; Kayacelebi H; Urhausen C; Piechotta M; Mischke R; Kramer S; Einspanier A; Oei CH; Günzel-Apel A
    Reprod Domest Anim; 2012 Dec; 47 Suppl 6():243-6. PubMed ID: 23279510
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prolactin influence on cytosol and nuclear androgen receptors in the ventral, dorsal, and lateral lobes of the rat prostate.
    Prins GS
    Endocrinology; 1987 Apr; 120(4):1457-64. PubMed ID: 3493896
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of dihydrotestosterone in benign prostatic hyperplasia.
    Carson C; Rittmaster R
    Urology; 2003 Apr; 61(4 Suppl 1):2-7. PubMed ID: 12657354
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Androgen-binding proteins in human benign prostatic hypertrophy.
    Rosen V; Jung I; Baulieu EE; Robel P
    J Clin Endocrinol Metab; 1975 Oct; 41(4):761-70. PubMed ID: 51854
    [TBL] [Abstract][Full Text] [Related]  

  • 26. (De)phosphorylation agents influence 5 alpha-reduction of testosterone in human prostate.
    Le Goff JM; Martin PM; Raynaud JP
    Endocrinology; 1988 Sep; 123(3):1693-5. PubMed ID: 2456919
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Three-month treatment with a long-acting gonadotropin-releasing hormone agonist of patients with benign prostatic hyperplasia: effects on tissue androgen concentration, 5 alpha-reductase activity and androgen receptor content.
    Forti G; Salerno R; Moneti G; Zoppi S; Fiorelli G; Marinoni T; Natali A; Costantini A; Serio M; Martini L
    J Clin Endocrinol Metab; 1989 Feb; 68(2):461-8. PubMed ID: 2465302
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Androgen dynamics in vitro in the human prostate gland. Effect of cyproterone and cyproterone acetate.
    Giorgi EP; Shirley IM; Grant JK; Stewart JC
    Biochem J; 1973 Mar; 132(3):465-74. PubMed ID: 4125095
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Androgens and androgen-receptors in prostate tissue from patients with benign prostatic hyperplasia: effects of cyproterone acetate.
    de Jong FH; Reuvers PJ; Bolt-de Vries J; Mulder E; Blom JH; Schroeder FH
    J Steroid Biochem Mol Biol; 1992 Mar; 42(1):49-55. PubMed ID: 1373073
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of castration, testosterone, estradiol, and prolactin on specific prolactin-binding activity in ventral prostate of male rats.
    Kledzik GS; Marshall S; Campbell GA; Gelato M; Meites J
    Endocrinology; 1976 Feb; 98(2):373-9. PubMed ID: 946169
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Androgen metabolism in the epithelial and stromal components of the human hyperplastic prostate.
    Habib FK; Tesdale AL; Chisholm GD; Busuttil A
    J Endocrinol; 1981 Oct; 91(1):23-32. PubMed ID: 6170712
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Subcellular distribution of zinc in the benign and malignant human prostate: evidence for a direct zinc androgen interaction.
    Leake A; Chrisholm GD; Busuttil A; Habib FK
    Acta Endocrinol (Copenh); 1984 Feb; 105(2):281-8. PubMed ID: 6198862
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Studies on the regulation of the concentration of androgens and androgen receptors in nuclei of prostatic cells.
    Bruchovsky N; Rennie PS; Vanson A
    Biochim Biophys Acta; 1975 Jun; 394(2):248-66. PubMed ID: 166692
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of MENT on primary cell cultures from benign prostatic hyperplasia and prostate carcinoma.
    Mendoza P; Sánchez C; Contreras HR; Vergara J; Acevedo C; Cabezas J; Huidobro C; Noé G; Castellón EA
    Int J Androl; 2009 Dec; 32(6):607-15. PubMed ID: 18637152
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro uptake of 3H testosterone and its conversion to dihydrotestosterone by prostatic carcinoma and other tissues.
    Prout GR; Kliman B; Daly JJ; Maclaughlin RA; Griffin PP
    J Urol; 1976 Nov; 116(5):603-10. PubMed ID: 62062
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of the nuclear 5 alpha-reduction of testosterone and androstenedione in human prostatic carcinoma and benign prostatic hyperplasia.
    Hudson RW; Wherrett D
    J Steroid Biochem; 1990 Feb; 35(2):231-6. PubMed ID: 1689784
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of androgens and/or prolactin on ventral prostate transplants.
    Edwards WD; Thomas JA
    Urol Int; 1977; 32(4):303-11. PubMed ID: 929774
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metabolism and action of steroid hormones on human benign prostatic hyperplasia and prostatic carcinoma grown in organ culture.
    Lasnitzki I
    J Steroid Biochem; 1979 Jul; 11(1B):625-30. PubMed ID: 90755
    [No Abstract]   [Full Text] [Related]  

  • 39. NAD(P)H-quinone oxidoreductase 1 silencing aggravates hormone-induced prostatic hyperplasia in mice.
    Kim HT; Kim YJ; Park SR; Ryu SY; Jung JY
    Andrologia; 2018 Apr; 50(3):. PubMed ID: 29110315
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A comparative study of binding, metabolism and endogenous levels of androgens in normal, hyperplastic and carcinomatous human prostate.
    Krieg M; Bartsch W; Janssen W; Voigt KD
    J Steroid Biochem; 1979 Jul; 11(1B):615-24. PubMed ID: 90754
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.